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Abstract: The sirolimus-eluting coronary stent received CE Mark approval in Europe in 
April 2002. In the US, FDA approval followed in April 2003. Since the preliminary results 
from the First-in-Man feasibility study were presented, several randomized, controlled trials 
have documented the profound antiproliferative effects of sirolimus, a macrolide antibiotic 
and potent cytostatic inhibitor of smooth muscle cell proliferation. Subsequently, the body of 
clinical evidence was increased by the second wave of evidence from trials in more complex 
lesions (such as in-stent restenosis, small vessels, chronic total occlusions) and “high-risk” 
patients such as those with diabetes. More recently we have had the opportunity to compare 
the two commercially available drug-eluting stents following the presentation of data from six 
head-to-head trials. As a result of numerous single and multi-center, national and international 
studies in which the safety and efﬁ  cacy of sirolimus-eluting coronary stents have been subjected 
to close scrutiny, the global interventional cardiology community now has a wealth of evidence 
in support of the use of this technology resulting in dramatically improved patient outcomes 
after percutaneous intervention. 
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Introduction
When the ﬁ  ndings from the ﬁ  rst 50 patients treated with angioplasty were ﬁ  rst pub-
lished, few would have predicted the dramatic increase in the use of percutaneous 
coronary interventions (PCI) with the associated explosion of clinical research and 
attendant information (Gruntzig et al 1979). There is no doubt that after the introduc-
tion of balloon angioplasty in 1977, intracoronary stenting was the most important 
development in the ﬁ  eld of percutaneous coronary revascularization. Nevertheless, the 
problem of post-angioplasty restenosis, or lumen re-narrowing several months after 
the index procedure, continued to challenge interventional cardiologists (Serruys 
et al 1994, 2005). The consequences of restenosis are many and varied, affecting 
every aspect of the perception and reality of angioplasty as a deﬁ  nitive therapeutic 
intervention. The recurrence of symptoms has a major impact on both the patient and 
the healthcare system. Repeat intervention (sometimes requiring coronary bypass 
graft surgery), repeat hospitalization, sometimes myocardial infarctions, and time off 
work, or in the case of the retiree, lost recreational time, impact on the quality of life 
of the patient, and the attendant costs all add to the economical burden of healthcare 
systems (Van Hout et al 1996; Morice et al 2002; Serruys et al 2005).
Pathophysiology of restenosis
Stent-induced restenosis involves a complex interplay of biological events. We now 
know that stent placement causes endothelial injury as well as deeper injury due to Vascular Health and Risk Management 2007:3(2) 192
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lacerations of the arterial wall. Injury stimulates smooth 
muscle cells to both proliferate excessively and migrate from 
the underlying vessel wall (Scott 2006).
Despite the scaffolding effect of the stent, the smooth 
muscle cells accumulate gradually, impinging upon the lumen. 
Tissue growth continues to be a problem because stents do not 
stop smooth muscle cell proliferation (Spier et al 1995). Cur-
rently, drug-eluting stents have emerged as the most promising 
approach in the ﬁ  ght against restenosis.
What is sirolimus?
Sirolimus was ﬁ  rst isolated from a soil micro-organism, 
Streptomyces hygroscopius, found on Easter Island, as 
reported by in 1975 (Vezina et al 1975). Rapa Nui is the 
local name for Easter Island, inspiring the compound’s well-
known common name of rapamycin. 
Crystalline sirolimus was puriﬁ  ed from fermentation 
media and found to be active against several strains of yeast 
and ﬁ  lamentous fungi. The produced streptomycyte was also 
active against some bacteria (Sehgal et al 1975; Vezina 
et al 1975), leading to the original classiﬁ  cation of sirolimus 
as an antifungal antibiotic (Singh et al 1979; Chakraborty 
et al 1995).
Since sirolimus is very lipid soluble (ie, lipophilic), 
almost no drug is released into the bloodstream during stent 
placement at the lesion site, and after stent implantation, the 
diffusion gradient favors elution into tissue, again limiting 
the amounts of circulating free sirolimus.
In addition to its antibiotic activity, it became apparent 
that sirolimus also possessed powerful anti-proliferative and 
immunosuppressant properties (Chang et al 1991). Sirolimus 
was shown to be a novel inhibitor of cellular proliferation, 
distinct from cyclosporin A in a variety of in vitro and in 
vivo models (Chang et al 1991; Stepkowski et al 1991; 
Groth et al 1999). The smooth muscle anti-proliferative 
properties have been characterized in numerous vascular 
models (Marx et al 1995; Poon et al 1996; Pham et al 1998; 
Poston et al 1999). 
In vivo studies in allograft and angioplasty models 
demonstrated the effectiveness of sirolimus in preventing 
tissue hyperplasia following vascular injury and led to is 
consideration as an agent for the prevention of restenosis 
(Gregory et al 1995; Gallo et al 1999). 
Clinical studies 
The First-in-Man feasibility study, conducted in Sao 
Paulo, Brazil and Rotterdam, the Netherlands showed the 
CYPHER® sirolimus-eluting stent (Cordis Corporation, 
Johnson & Johnson, Warren, NJ, USA) to be remarkably 
effective in eliminating the occurrence of restenosis (Sousa 
et al 2001). 
These early results were followed by the unprecedented 
ﬁ  ndings from the RAVEL trial, the ﬁ  rst double blind, ran-
domized, controlled trial of a drug-eluting stent (Morice 
et al 2002). These exceptional results are well known and 
have been replicated in three additional randomized, con-
trolled trials – SIRIUS, E-SIRIUS, and C-SIRIUS (Moses 
et al 2003; Schofer et al 2003; Schampaert et al 2004).
Subsequently, the ﬁ  ndings from the First-in-Man study 
study show that the efﬁ  cacy and safety of sirolimus have 
been sustained out to 4 years (Sousa et al 2005).
Since the preliminary results from the First-in-Man 
feasibility study were presented, the CYPHER stent is 
currently available in more than 80 countries and has been 
used by doctors to treat more than 2 million patients world-
wide (Cordis Corporation, Warren, New Jersey, USA, press 
release 26 April 2006). The sirolimus-eluting coronary stent 
(SES) is the most studied drug-eluting stent today with the 
largest body of clinical evidence demonstrating long-term 
safety and efﬁ  cacy of its drug and polymer (Fig. 1). In 
addition, the SES was shown to yield the same strong patient 
outcomes with or without balloon pre-dilation, according 
to the comparison of intravascular ultrasound results from 
the multicenter, randomized E-SIRIUS and SIRIUS trials 
(Hoffmann et al 2005). 
However, the main criticism of any controlled clinical 
program is that by its very nature, patient entry is limited 
by the strict inclusion and exclusion criteria. It is against 
this background that several prospective registry studies 
have begun, in order to collect a large series of data in more 
challenging lesions (such as small vessels, long lesions, 
bifurcations, chronic total occlusions and left main disease) 
and patient populations (acute coronary syndromes and 
multi-vessel disease). 
Management of complex lesions 
and “high-risk” patients 
As operator experience with SES grows, and the clinical 
evidence base is enhanced following the outcomes from a 
series of independent, “head-to-head” comparative trials, 
so SES are being used to treat increasingly complex lesions 
and patients considered to be “high risk”. Among the factors 
associated with this changing face of interventional cardiol-
ogy three stand out:Vascular Health and Risk Management 2007:3(2) 193
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1.  The rising epidemic of diabetes, more complex lesions 
(small vessels, more extensive and diffuse disease, multi-
vessel disease, total occlusions, left main disease) (Urban 
et al 2006).
2.  The rising epidemic of obesity – associated with meta-
bolic syndrome (hypertension, dyslipidemia, high fasting 
glucose) and early onset of atherosclerosis.
3.  The advent of drug-eluting stents – resulting in improved 
outcomes and their resultant use in a broader range of 
indications (including diabetes/multi-vessel disease, 
in-stent restenosis, chronic total occlusions, bifurcations, 
saphenous vein grafts, and left main stem disease).
Following the First-in-Man feasibility study and the series 
of trials in which SES was compared with bare metal stents 
in relatively simple lesions, the body of clinical evidence was 
increased by additional data from trials on more complex 
lesions such as small vessels (Meier et al 2006; Ardis-
sino et al 2004), chronic total occlusions (Jang et al 2006; 
Lotan et al 2006; Suttorp et al 2006), in-stent restenosis 
(Alfonso et al 2006; Holmes et al 2006), multi-vessel disease 
(Serruys et al 2005), acute myocardial infarction (Spaulding 
et al 2006), and patients with diabetes (Ortolani et al 2005; 
Sabate et al 2006). 
Additional data from the SIRIUS trial serve to conﬁ  rm the 
durability of outcomes with CYPHER stent and the impor-
tance of inhibiting neointimal hyperplasia (NIH) and late loss 
as much as possible from the start. SIRIUS follow-up results 
presented at ACC showed that the highly signiﬁ  cant differences 
Figure 1 Sirolimus-eluting coronary stent is the most studied of all drug-eluting stents, with data generated from randomized controlled trials and registries.
AMI, acute myocardial infarction; CTO, chronic total occlusions; DM, diabetes mellitus; ISR, in-stent restenosis; MVD, multi vessel disease. Vascular Health and Risk Management 2007:3(2) 194
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(p < 0.0001) between the CYPHER stent and bare metal 
control stent for all clinical event endpoints were sustained 
at 3-years. Furthermore, when these results are compared 
with the 9m follow-up data, SIRIUS demonstrates that the 
clinical beneﬁ  t of CYPHER stent over bare metal stents 
increases from 9 to 12 months (by an average of 24%) and 
this remains virtually unchanged at 3 years with no evidence 
of late “catch-up” in restenosis (Moses et al 2003). 
Comparative trials
More recently, we have had the opportunity to compare the 
SES and paclitaxel drug-eluting stents (PES) following the 
presentation of data from a total of ten head-to-head trials 
(Table 1).
ISAR-DESIRE was the ﬁ  rst randomized trial to show 
that drug-eluting stents provide results superior to those 
achieved with standard percutaneous transluminal coronary 
angioplasty (PTCA) in the treatment of in-stent restenosis. 
Secondary analysis also suggests an advantage of SES over 
PES in terms of clinical restenosis rates in this indication 
(SES: 14.3%, PES: 21.7%) (Kastrati et al 2005a).
Results from SIRTAX, a Swiss study involving 1005 
patients, revealed that when compared with TAXUS, the 
CYPHER stent had signiﬁ  cantly lower rates of death, 
myocardial infarction (MI), or target lesion revascularization 
(TLR) at 9 months – the composite primary endpoint (6.2% 
vs 10.8%, p < 0.009). What makes these ﬁ  ndings all the more 
impressive is the fact that SIRTAX is an “all-comers” trial 
with a very complex patient population which included those 
with acute coronary syndromes, chronic total occlusions and 
bifurcation lesions (Windecker et al 2005).
Following the pattern set by earlier comparisons of drug-
eluting stents, diabetic patients treated in ISAR-DIABETES 
trial, revealed CYPHER to have a signiﬁ  cantly superior 
suppression of neointimal hyperplasia, as measured by both 
in-stent and in-segment late lumen loss (Dibra et al 2005). This 
ﬁ  nding corresponds to a signiﬁ  cant reduction in restenosis 
rates (16.5% in-segment restenosis in the paclitaxel group 
versus 6.9% in the sirolimus group) and a much lower need 
for repeat intervention with CYPHER stent. Target lesion 
revascularization rates were 12.0% and 6.4% for the pacli-
taxel and sirolimus groups respectively (Dibra et al 2005).
The results from the REALITY trial show no signiﬁ  cant 
differences in the primary end point of binary restenosis at 
8 months among the 1386 patients treated with either the 
CYPHER or the TAXUS. Late loss and diameter stenosis 
were signiﬁ  cantly less in the CYPHER-treated patients, but 
this did not translate into differences in the secondary end 
points of target lesion and target vessel revascularizations 
at one year. The composite end point of cardiac death, MI, 
coronary artery bypass grafting (CABG), or repeat percutane-
ous coronary intervention (PCI) (MACE) at one year was no 
different between the two groups. REALITY also does not 
settle the question of stent thrombosis, which trended higher 
in the Taxus-treated patients (Morice et al 2006). The issue 
of stent thrombosis is discussed below.
Similarly, TAXI, a prospective randomized comparison 
between PES and SES in the real world of interventional 
cardiology conﬁ  rmed that the high success rate obtained with 
both stents in randomized trials can be replicated in routine 
clinical practice. A total of 202 patients were enrolled into 
the study. One hundred patients were treated with a PES and 
102 received an SES. Target lesion revascularisation rates 
were low in both groups: 1% with paclitaxel and 3% with 
sirolimus. The investigators acknowledged that in this small 
group of patients they were unable to show any advantage 
of one stent over the other (Goy et al 2005).
ISAR-SMART 3 involved a total of 360 patients undergo-
ing PCI for de novo lesions in native coronary arteries with 
a diameter of <2.80 mm. They were randomly assigned to 
receive either an SES or a PES. The primary endpoint was 
in-stent late luminal loss, the primary endpoint, was 0.32 mm, 
which was greater than that in the SES group, failing to show 
non-inferiority of the PES to the SES. Angiographic resteno-
sis was reported in 19.0% of the PES cohort as compared with 
11.4% in those treated with the SES. Similarly, target lesion 
revascularization rates were 14.7% and 6.6% for the paclitaxel 
and sirolimus groups respectively (Mehilli et al 2006).
Conducted at Cordoba and Las Palmas in Spain, the 
CORPAL trial evaluated 1182 lesions in 910 patients identi-
ﬁ  ed as being at high risk for restenosis. Consecutive patients 
with documented myocardial ischemia secondary to coronary 
lesions were randomized to either SES or PES. There were 
no signiﬁ  cant differences in terms of immediate or 1-month 
follow-up. However, late evaluation (15 ± 8 months) did 
reveal differences in terms of restenosis rates (15% vs 23% 
for SES and PES respectively, and target lesion revascular-
ization (4% vs 7%) (Suarez de Lezo et al 2005).
Data from the multi-centre, prospective, randomized 
controlled LONG-DES II trial revealed that patients treated 
with SES had signiﬁ  cantly less in-stent late loss than those 
treated with paclitaxel-eluting stents (0.05 ± 0.22 mm vs 
0.25 ± 0.35 mm). Major adverse cardiac event rates were 3% 
for sirolimus vs 10.3% for paclitaxel (Hong et al 2006).Vascular Health and Risk Management 2007:3(2) 195
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Table 1 Comparative trials: sirolimus-eluting stents and paclitaxel-eluting stents 
Author   Trial  Indication  Patients (N)  Outcomes
Kastrati et al 2005a  ISAR-DESIRE  In-stent   300s  Angiographic restenosis
  (RCT)  restenosis    SES: 14.3% PES: 21.7% PTCA: 44.6%
        Target vessel revascularization
        SES: 8.0% PES: 19.0% PTCA: 33.0%
Dibra et al 2005  ISAR-DIABTES  Diabetes  250  In-segment restenosis
  (RCT)      SES: 6.9% PES: 16.5%
        Target lesion revascularisation 
        SES: 6.4% PES: 12.0%
Mehilli et al 2006   ISAR-SMART 3   Small coronary  360  Angiographic restenosis
  (RCT)  arteries    SES: 11.4% PES: 19.0%
        Target lesion revascularization
        SES: 6.6% PES: 14.7%
Windecker   SIRTAX (RCT)  All comer  1.012  MACE
et al 2005        SES: 6.2% PES: 9.8%
        Target lesion revascularisation
        SES: 4.8% PES: 8.3%
Morice et al 2006  REALITY (RCT)  De novo   1386  In-lesion restenosis
    lesions    SES: 9.6% PES: 11.1%
Pan et al 2007  CORPAL  Bifurcation   205  Target lesion revascularization
    lesions    SES: 4% PES: 13%
Lee et al 2006  PROSIT (RCT)  AMI  231  MACE rates @ 9 months
        SES: 6.9% PES: 14.8%
Park et al 2006  Long Lesions II  Lesion   500  In-segment restenosis
    length    SES: 3.0% PES: 10.3%
    >25 mm    MACE rates @ 9 months
        SES: 3.0% PES: 7.8%
Goy et al 2005  TAXI   All comer  202  MACE rates @ 7 months
  (RCT)      SES: 6% PES: 4%
        Target lesion revascularization
        SES: 3% PES: 1%
Kaiser et al 2005  BASKET  All comer  826  Target vessel revascularisation
  (RCT)      SES: 1.5% PES: 2.6%
        Target lesion revascularization
        SES: 0.8% PES: 0.7%
Abbreviations: RCT, randomized controlled trial; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents.
Results from PROSIT, the prosective, randomized, 
independent, controlled trial, in acute MI patients, show that 
rates of major adverse cardiac events (MACE) at 9-month 
follow-up were 6.9% (sirolimus) and 14.8% (paclitaxel). The 
MACE rates in the paclitaxel cohort were driven by death 
(7.8%) and TLR (7.8%). 231 patients were enrolled into the 
study, randomized to either SES (n = 116) or PES stents 
(n = 115) (Lee et al 2006).
Similarly, data from a meta-analysis, in which the results 
from six randomized controlled trials were combined so as 
to compare the Cypher and Taxus drug-eluting stents. The 
six trials included in the meta-analysis were CORPAL, 
ISAR-DIABETES, ISAR-DESIRE, REALITY, SIRTAX, 
and TAXI. A total of 3669 patients with 4878 lesions were 
treated with either CYPHER or TAXUS stents in the seven 
trials. The analysis revealed that patients receiving SES 
had a signiﬁ  cantly lower risk of restenosis and target vessel 
revascularization compared with those receiving PES. Rates 
of death, death or MI, and stent thrombosis were similar 
(Kastrati et al 2006b). 
Further data on the use of CYPHER stents to treat 
complex lesions come from a Danish study. The ScandStent 
(The Stenting of Coronary Arteries in Non-Stress/Benestent 
Disease Trial) study is a multicentre trial randomized 322 
patients with complex coronary lesions to either the CYPHER 
stent or bare metal control stent. It provides independent 
conﬁ  rmation that the superiority of CYPHER over bare metal 
stents seen in the pivotal trials in less complex lesions also 
holds for more complex lesions (Kelbaek et al 2006).
Follow-up results from ARTS II (Arterial Revasculariza-
tion Therapies Study part II of the CYPHER SES in the treat-
ment of patients with multi-vessel de novo coronary artery Vascular Health and Risk Management 2007:3(2) 196
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lesions) add to the growing evidence in support of the use 
of SES in the treatment of multi-vessel disease. However, as 
with all “new” technologies, continued careful investigation 
will be an essential aid to appropriate patient selection and 
treatment when treating patients with more complex lesions 
and multi-vessel disease (Serruys et al 2005).
Late loss: a key measurement 
in differentiating drug-eluting
stents (DES)
Late loss is the angiographic metric that allows post-stent 
neointimal hyperplasia to be most accurately and reliably 
quantiﬁ  ed. It reﬂ  ects the ability of DES to inhibit the inﬂ  am-
matory and hyperplastic processes that translate into adverse 
clinical outcomes such as binary restenosis and target lesion 
revascularization (Mauri et al 2005). 
When the CYPHER vs TAXUS head-to-head trials are 
organized in order of increasing patient and lesion complex-
ity (REALITY → SIRTAX → ISAR-DIABETES → ISAR-
DESIRE) a trend emerges showing an association between 
lower late loss and superior clinical outcomes (restenosis and 
TLR). As the patient population becomes more complex, the 
gap between CYPHER and TAXUS in terms of late loss and 
restenosis widens, showing an increasing beneﬁ  t with the 
CYPHER stent (Fig. 2).
It has been seen that there is an association between late 
loss, restenosis, and complexity in CYPHER vs TAXUS 
studies. Late loss and in-stent restenosis increase as patient 
populations become more complex, and these increases are 
consistently higher in TAXUS populations. This trend is 
expressed as a “complexity curve”. When the ENDEAVOR 
III results for late loss are mapped onto this complexity curve 
it can be seen that the late loss and restenosis rate are high 
considering the relatively straightforward patient population 
evaluated in ENDEAVOR III (Fig. 3).
Key characteristics of an ideal DES
To be successful, DES must combine several key character-
istics. The ﬁ  rst requirement is for a drug that reliably blocks 
smooth muscle cell hyperplasia and reduces vascular inﬂ  am-
mation while allowing healing to occur. The second require-
ment is for a stent design that permits homogenous delivery 
of optimal drug dosages using a system, which delivers the 
drug in a predictable fashion. The CYPHER SES brings 
together nearly ideal solutions that meet all three criteria. The 
unique combination of the highly effective anti-proliferative 
agent, sirolimus, a closed-cell design, and a biocompatible 
polymer results in exceptional outcomes. This combination 
of three elements produces optimal drug delivery; controlled, 
precise drug release; and marked reduction of late loss with 
a favorable safety proﬁ  le.
Sirolimus – safety and tolerability
Safety of a broad therapeutic window
Sirolimus has been shown to have a broad therapeutic win-
dow. In pre-clinical animal trials, sirolimus has demonstrated 
Table 2 Rate of late-stent thrombosis: sirolimus-eluting, paclitaxel-eluting, drug-eluting, and bare metal stents
Author   Trial  Patients (N)  Length of    Thrombosis rates by stent type
     follow-up    (SES/PES/DES/BMS)
Kereiakes et al 2006  Pooled analysis  SES: 337   1080 days  SES: 0% 
    BMS: 0.4%    BMS: 238 
Moreno et al 2005  Meta-analysis  DES: 2602  –  DES: 0.58%  SES: 0.11%
    BMS: 2428    BMS: 0.54%  PES: 0.29%
Park et al 2006  Single center,   SES: 1545  18 months  DES: 0.8%
  all comers  PES: 366 
Schampaert et al 2004  Pooled   SES: 758  2 years  SES: 0.4%
  analysis  BMS: 752    BMS: 0.5%
Bavry et al 2005  Meta-analysis  SES: 1515  13.5 months  SES: 0.07%
   BMS: 1448   BMS:  0.48%
Weisz et al 2006  SIRIUS trial  SES: 533  361–720 days  SES: 0.9%
   BMS:  525    BMS: 1.5%
Urban et al 2006  e-CYPHER   SES: 15157  12 months  SES: 0.19%
  registry
lakovou 2005   Prospective  SES: 1062  9 months  SES: 0.8%
  observational   PES: 1167    PES: 1.7%
 cohort  study
Abbreviations: BMS, bare metal stents; DES, drug-eluting stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents. Vascular Health and Risk Management 2007:3(2) 197
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biological activity in doses ranging from 18 to 1200 µg 
without displaying toxicity to the vessel wall (Cordis Cor-
poration, Warren, New Jersey, USA, data on ﬁ  le). 
•  The highest dose now tested is approximately 6 times 
that of the CYPHER stent, with no adverse effects (no 
evidence of necrosis, aneurysm, or other pathology with 
1200 µg in an exaggerated dose study.
•  The broad therapeutic proﬁ  le of sirolimus means that over-
lapping stents can be deployed without the risk of toxicity 
due to overdosing (Suzuki et al 2001). SIRIUS data from 
over 27% of patients with 2 or more overlapping stents 
demonstrate the safety and efﬁ  cacy when overlapping 
SES (Moses et al 2003; Munoz et al 2004). Additional 
data come from the RESEARCH registry, based on a 
study population of patients who had a combination of ≥2 
overlapping stents at a minimum length of 41 mm (ie, one 
33 mm SES overlapping an 8 mm SES) to treat native 
de novo coronary lesions. The investigators monitored 
the incidence of major cardiac adverse events (death, 
non-fatal MI, and TLR). Clinical follow-up was available 
for all patients at a mean of 320 days (range 265–442). 
Angiographic follow-up at 6 months was obtained in 67 
patients (71%). Binary restenosis rate was 11.9% and 
in-stent late loss was 0.13 +/– 0.47 mm. At long-term 
follow-up (mean 320 days), there were 2 deaths (2.1%), 
and the overall incidence of major cardiac events was 
8.3%. The investigators concluded that SES implantation 
appears safe and effective for de novo coronary lesions 
requiring multiple stent placement over a very long vessel 
segment (Aoki et al 2005).
•  The ﬂ  at dose-response curve of sirolimus demonstrates 
a consistent, homogeneous anti-proliferative and anti-in-
ﬂ  ammatory effect at all doses evaluated, with no indication 
of cytotoxicity (Cordis Corporation, data on ﬁ  le). 
Stent thrombosis
Since their introduction, more than 2 million patients, often 
with complex lesions, diabetes, and acute MI, have been 
treated with an SES. Although the published data support the 
claim that DES are safe and effective there have been concerns 
raised about the incidence of very late stent thrombosis (more 
than 1-year after implantation) compared with the use of bare 
metal stents (Iakovou et al 2005; Colombo and Corbett 2006). 
This concern has been fuelled by individual case reports and 
new long-term data from TAXUS-II, -IV, and -V and 
the Basel Stent Cost-Effectiveness Trial (BASKET) studies 
(American College of Cardiology  Scientiﬁ  c Sessions 2006). 
However, despite these concerns over the long-term safety 
of DES, the actual incidence of stent thrombosis after 1-year 
is unknown (Park et al 2006).
In the absence of an internationally accepted deﬁ  nition of 
late stent thrombosis or any fact-based evidence concerning the 
Figure 2 In higher risk cohorts, differences in late loss are more strongly associated with risk of target lesion revascularization. Vascular Health and Risk Management 2007:3(2) 198
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incidence of stent thrombosis, a review of the literature suggests 
that the incidence of late stent thrombosis with SES is compa-
rable with that of bare metal stents (Bavry et al 2005; Iakovou 
et al 2005; Moreno et al 2005; Kereiakes et al 2006; Weisz et al 
2006; Park et al 2006; Schampaert et al 2006; Urban et al 2006). 
The individual trials/analyses are shown in Table 1.
It has been suggested that treatment with a drug-eluting 
stent results in delayed arterial healing when compared with 
bare metal stents of similar implant duration. It has also been 
postulated that the cause of late stent thrombosis associated 
with DES is multifactorial, with delayed healing in combina-
tion with other clinical and procedural risk factors playing a 
role (Joner et al 2006). The available evidence indicates that 
the predictors of stent thrombosis are premature anti-platelet 
therapy interruption, primary stenting in acute MI, and total 
stent length. However, if we are to gain a better understand-
ing of the problems of DES thrombosis it would appear that 
an extended period of follow-up in a randomized, controlled 
trial or a large registry such as e-SELECT will be necessary. 
Thankfully, the incidence of late stent thrombosis appears to 
be very rare. Nevertheless, its impact can be tragic.
Closed cell design
The distribution of an eluted drug in the tissue of a vessel 
wall is not at all homogenous, and this might reﬂ  ect the 
pattern of the stent struts. While the dose distribution may 
be sub-therapeutic in one spot, it may be toxic in the direct 
vicinity of the struts. Homogenous drug distribution would 
also require a symmetric deployment of a stent, which does 
not necessarily happen in the real world. Overlapping stents 
may lead to doubling of the intended dose, and longitudinally 
the drug tissue levels may vary considerably from proximal 
to distal end. An open cell versus a closed cell stent design 
has different characteristic patterns of apposition to the cell 
wall, leading again to a difference in the delivered dose, with a 
closed cell design appearing to offer better drug distribution.
The CYPHER stent’s closed-cell design results in uni-
form vessel coverage, making it an optimal platform for 
drug delivery. With a closed-cell design, when the stent is 
deployed in a tortuous site, cell size is minimally affected 
either on the outer aspect or inner aspect of the bend, and 
uniform vessel coverage and dosing are maintained. In con-
trast, with open-cell design, tortuosity can cause dramatic 
changes in cell sizes. This may result in both excessively 
large cells on the outer side of the bend and small cell sizes 
on the inner surface of the bend. Consequently, there is 
non-uniform coverage of the vessel wall and non-uniform 
dosing, both with potential under dosing and over dosing. 
Closed-cell design results in optimal drug delivery to tortuous 
anatomy, for example, in lesions of the right coronary artery 
and in eccentric lesions, as encountered in highly asymmetric 
proximal left anterior descending plaque.
Figure 3 In higher risk cohorts, differences in late loss are more strongly associated with risk of restenosis.
Abbreviations: TLR, target lesion revascularization.Vascular Health and Risk Management 2007:3(2) 199
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Polymer
For drug distribution and safety one needs to consider the 
relationship between the stent design and the drug tissue con-
centration. Currently used polymers for stent coatings have 
been proven safe. They release drugs at predictable rates and 
it is interesting to observe that fast and slow release polymers 
lead to similar tissue concentrations. The tissue penetration 
depends more on the hydrophobic or hydrophilic properties 
of the drug. A hydrophobic or lipophilic drug will easily 
penetrate and be found in high concentrations regardless of 
slow or fast release. The difference between slow and fast 
release may lie in the tissue toxicity; a high tissue level, built 
up quickly, may have toxic necrotic effects, as seen with 
paclitaxel. This can lead to thrombus formation; the stent may 
no longer be adherent to the necrotic wall. Overall, clinical 
and histological toxicity is a concern.
Controlled release is crucial to the efﬁ  cacy of DES. The 
CYPHER stent has a unique polymer coating, which allows 
for localized delivery of sirolimus precisely to the site of the 
lesion. It contains a speciﬁ  c concentration of sirolimus and 
the polymer ensures that the drug does not wash off dur-
ing the most time-intensive procedures. The polymer also 
ensures that there is no rapid “dumping” of the drug, but 
rather tightly regulated drug release over a deﬁ  ned period 
of time. Essentially all the drug is delivered in the ﬁ  rst 3 
months after implantation.
Impact on patients
Over the past 25 years coronary angioplasty has developed 
into a highly sophisticated series of techniques that has the 
potential to match surgery, and in many cases surpass it. 
Implantation of SES has revolutionized the ﬁ  eld of percu-
taneous coronary angioplasty with an impressive reduction 
of in-stent restenosis compared with bare metal stents. 
This advantage translates into fewer repeat treatments for 
the patient, a reduction in the need for surgical interven-
tion, and the ability to treat more patients. Thankfully, the 
incidence of stent thrombosis appears to be in line with that 
of bare metal stents. That being said, the ability to identify 
the patient who is at risk of stent thrombosis is a major and 
urgent challenge.
Conclusions and place in therapy
The introduction of SES was a major breakthrough for 
interventional cardiology. Many large, randomized, clini-
cal trials using SES have shown a remarkable reduction in 
angiographic restenosis and target vessel revascularization 
compared with bare metal stents. The results of these trials 
also appear to be supported by evidence from everyday prac-
tice and non-controlled clinical trials. However, the expanded 
applications of SES, especially in treating complex lesions 
such as left main disease, acute MI, and saphenous vein graft 
lesions, are still under evaluation with ongoing studies. The 
adoption of SES in all percutaneous coronary intervention 
may become a reality in the near future.
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